Jeremy Feldman, MD
Pulmonary Disease · Bend, ORNPI 1689681025
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 38.3% of the total. Among pulmonary disease clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $1142.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$175K
- United Therapeutics Corporation$129K
- Bayer$73K
- Merck$60K
- Boehringer Ingelheim$7K
- Sumitomo Pharma America, Inc.$6K
- plus $6K from 21 others
Across 307 payments — averaging $5198.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$478K
- Medtronic$289K
- Actelion Pharmaceuticals, Ltd$267K
- Janssen Research & Development, LLC$170K
- United Therapeutics Corporation$136K
- Acceleron Pharma, Inc.$107K
- plus $150K from 6 others
What the payments were for
- Consulting fees$133,56229%
- Speaking & faculty fees$272,36460%
- Travel & lodging$41,8149%
- Food & beverage$7,9012%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 165 | $174,643 |
| United Therapeutics Corporation | 122 | $129,008 |
| Bayer | 16 | $72,552 |
| Merck | 44 | $60,199 |
| Boehringer Ingelheim | 10 | $7,433 |
| Sumitomo Pharma America, Inc. | 9 | $5,637 |
| Gilead | 7 | $4,403 |
| Medtronic | 1 | $550 |
| Vertex | 1 | $500 |
| Inari Medical, Inc. | 1 | $296 |
| Insmed, Inc. | 3 | $63 |
| Amgen | 2 | $57 |
| Pulmonx Corporation | 2 | $38 |
| Sanofi | 2 | $31 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| GSK | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Olympus America Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Abbott | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Viiv Healthcare Company | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$455,658 in reported general payments places this provider in the 95th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 45 | $1,072,128 |
| OfevNintedanib Esylate | 73 | $924,992 |
| OpsumitMacitentan | 52 | $634,637 |
| Orenitram ErTreprostinil Diolamine | 24 | $364,323 |
| WinrevairSotatercept-Csrk | 17 | $343,975 |
| TreprostinilTreprostinil Sodium | 11 | $215,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 228 | $191,002 |
| Ambrisentan | 28 | $144,315 |
| JardianceEmpagliflozin | 158 | $131,889 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 97 | $57,199 |
| EliquisApixaban | 70 | $55,972 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $49,831 |
| Spiriva RespimatTiotropium Bromide | 37 | $26,904 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $15,109 |
| Pirfenidone | 22 | $14,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Stiolto Respimat, Spiriva Respimat | $7,433 | $1,133,616334 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $174,643 | $634,63752 claims |
| MerckWinrevair | $60,199 | $343,97517 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $29 | $277,559383 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Bend
- Matthew HegewaldBend$94K
- Louis D'avignonBend$4K
- Kevin ShererBend$2K
- Thomas KelleyBend$2K
- Gregory BlairBend$782
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.